CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma

Published:2018-05-29 Issue:6 Volume:9 Page:
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Lu Shuai,Yao Yao,Xu Guolong,Zhou Chao,Zhang Yuan,Sun Jie,Jiang Runqiu,Shao Qing,Chen Yun

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/s41419-018-0681-z.pdf

Reference51 articles.

1. Bruix, J. & Llovet, J. M. HCC surveillance: who is the target population? Hepatology 37, 507–509 (2003).

2. Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl. Cancer Inst. 100, 698–711 (2008).

3. Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 33, 550–558 (2015).

4. Maluccio, M. & Covey, A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. Cancer J. Clin. 62, 394–399 (2012).

5. Bruix, J., Gores, G. J. & Mazzaferro, V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63, 844–855 (2014).

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy;Frontiers in Immunology;2024-09-09

2. Substituted indole derivatives as UNC-51-like kinase 1 inhibitors: Design, synthesis and anti-hepatocellular carcinoma activity;Biomedicine & Pharmacotherapy;2024-09

3. Unravelling CD24‐Siglec‐10 pathway: Cancer immunotherapy from basic science to clinical studies;Immunology;2024-08-11

4. CD24 promotes metastasis and chemoresistance by directly targeting Arf6-ERK pathway in esophageal squamous cell carcinoma;Cancer Letters;2024-07

5. Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies;ACS Omega;2024-06-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3